Datavault AI (NASDAQ: DVLT) has entered into a nonbinding letter of intent to acquire a 19.9% equity interest in DataMEDS AI Inc. (NASDAQ: MEDS) in exchange for expanding its existing technology license with the company, according to an announcement by DefenseWireNews.
The proposed transaction matters because it would restructure how the two companies share the economics of health care data technology. Under the terms, Datavault AI would retain ownership of its underlying intellectual property while potentially generating royalty revenue from commercialization of the licensed technologies. DataMEDS would assume commercialization costs, and Datavault AI would have the right to designate one director to the DataMEDS board following closing.
The company believes a fourth-quarter 2026 closing is achievable, subject to due diligence, definitive agreements and customary closing conditions. The letter of intent does not obligate either party to complete the transaction, a caveat that leaves the deal open to change or termination before any definitive agreement is reached.
The proposed expanded license would build on DataMEDS' existing PharmacyChain platform and EinsteinRx AI capabilities, incorporating Datavault AI Health technologies designed to support patient-controlled health data access, management, monetization and tokenization across pharmacy, laboratory, wearable and other health care environments. For readers and industry observers, the arrangement signals continued convergence between AI-driven data monetization and pharmacy operations, a combination that could reshape how patient-controlled health records are handled and commercialized.
The initiative is part of broader efforts by DataMEDS to expand its health care technology capabilities through arrangements with several companies, including EOS Technology Holdings, Scilex Holding Company, HealthBridge Advisors and REBOOT Health AI. For Datavault AI, the proposed stake offers a path to participate in that expansion without directly bearing commercialization costs.
Datavault AI describes itself as leading the way in AI-driven data experiences, valuation and monetization of assets in the Web 3.0 environment. Its cloud-based platform serves multiple industries through its Acoustic Sciences and Data Sciences divisions, with the Data Science division leveraging Web 3.0 and high-performance computing for experiential data perception, valuation and secure monetization. The company is headquartered in Philadelphia, PA, and more information is available at https://dvlt.ai.
For investors tracking the company, the latest news and updates relating to DVLT are available in the company's newsroom at https://ibn.fm/DVLT, and the full press release can be viewed at https://ibn.fm/Q8IGK.
The announcement was distributed through DefenseWireNews, a specialized communications platform focused on defense contractors, aerospace firms, cybersecurity leaders, advanced manufacturing innovators and other mission-critical companies. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which delivers wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and tailored corporate communications solutions. Full terms of use and disclaimers applicable to all content provided by DWN are available at https://www.DefenseWireNews.com/Disclaimer.
